表紙
市場調査レポート

マレーシアの医薬品市場

The Pharmaceutical Market: Malaysia

発行 Espicom Business Intelligence 商品コード 242166
出版日 ページ情報 英文 144 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
マレーシアの医薬品市場 The Pharmaceutical Market: Malaysia
出版日: 2014年03月11日 ページ情報: 英文 144 Pages
担当者のコメント
このシリーズは、他にも調査対象国がございます。詳細はお問合せください。
概要

当レポートでは、マレーシアの医薬品市場について、 市場全体の動向と法規制、医薬品流通チャネルなどを分析し、 OTC医薬品、ジェネリック医薬品、バイオ医薬品・バイオシミラーなどのセグメント別の動向、 市場の機会と課題などを併せ、概略下記の構成でお届けいたします。

目次

エグゼクティブサマリー

  • スナップショット: Espicom の戦略的分析
  • スナップショット: 主要データ予測

マクロ環境

  • 政治環境
  • 経済環境
  • 法環境
  • 人口統計

疫学

  • 病気の負荷
  • 羅漢率

ヘルスケア - 保健統計付

  • 組織・機構
  • 医療費
  • インフラストラクチャー
  • サービス
  • 労働力

規制関連情報

  • 国際機関
  • 国内当局
  • 市場登録
  • プロモーション

価格決定および償還

  • 価格決定

流通チャネル

  • 医薬品 卸売り
  • 医薬品 小売

市場分析

  • 規模
  • 製品開発
  • 製造
  • 貿易

競合状況

  • 事業者団体
  • 企業情報

OTC 医薬品

  • 競合状況

ジェネリック医薬品

  • 競合状況

生物製剤/バイオシミラー

  • 規制
  • 市場規模
  • 調査・開発
  • 競合状況

結び: 機会と課題

  • Espicom の戦略的分析

関係各機関・組織一覧

  • 政府組織
  • 製薬会社
  • 業界団体

図表


このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Summary

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context.

The reports provide:

  • Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
  • Specialised intelligence on OTCs, generics, biologics and biosimilars.
  • Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
  • A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Description

THE PHARMACEUTICAL MARKET: MALAYSIA - REVIEW

The Malaysian pharmaceutical market is small and relies heavily on the import of medicaments. Espicom projects the market to grow at a healthy CAGR in the forecast period. However, it will remain as the fifth smallest pharmaceutical market in the Asia Pacific region in size terms by 2016. There are around 250 Malaysian pharmaceutical manufacturers licensed by the Drug Control Authority, although over two-thirds of these are traditional medicine manufacturers. There is little multinational manufacturing activity in the country due to strict regulations, although these may be relaxed in the future. Ranbaxy and GSK are the only examples of large global multinational companies that have manufacturing operations in the country. Malaysia is heavily dependent on the imports of retail medicaments, which represent around three-quarters of total imports. As most pharmaceutical manufacturing is for local consumption, the balance of pharmaceutical trade will remain considerably negative, and the deficit is likely to increase in the forecast period.

The macroenvironment will be defined by an increase in GDP and population during the forecast period. Politically, the government aims to reduce its fiscal deficit in 2011, following a recent period of fiscal stimulus and loose monetary policy. Economically, Malaysia will be the ninth largest economy in the Asia Pacific region covered by Espicom in 2016. In terms of GDP per capita, Malaysia will rank eighth. Legally, Malaysia remains on the US Trade Representative's (USTR) Watch List in 2011, despite the government strengthening its IPR protection and enforcement. Demographically, the population is estimated to have a high growth rate. By 2016, the EIU projects that the population of Malaysia will be the 11th largest in the Asia Pacific region. The elderly population is expected to grow in the forecast period. Malaysia has a largely young population, with those aged between 0-14 years old making up nearly a third of the total.

The government has identified biotechnology as one of the core technologies to accelerate the transformation of Malaysia into a knowledge-based economy and an industrialised nation by year 2020. The Malaysian Biotechnology Corporation (BiotechCorp) is the leading agency responsible for the co-ordinated implementation of the National Biotechnology Policy (NBP). The most important Malaysian biologic manufacturers include Bioven, CCM Duopharma, Inno Biologics and Ninebio. The National Pharmaceutical Control Bureau (NPCB) has adopted the Guidance Document and Guidelines for the Registration of Biosimilars, making Malaysia only the second country, after Australia, in the Asia Pacific region to adopt regulations for biosimilar registration. There have been a number of competitive strategies completed over the last 12 months: Agila Specialities has agreed to establish a biopharmaceuticals facility at Bio-XCell park; US-based Viropro has acquired Alpha Biologics; and Indian-based Avesthage, in partnership with Inno Biologics, has manufactured clinical grade darbepoetin alfa, its biosimilar version of Amgen's Aranesp.

ENHANCED STRATEGIC INTELLIGENCE

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context.

The reports provide:

  • Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
  • Specialised intelligence on OTCs, generics, biologics and biosimilars.
  • Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
  • A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

About Espicom Business Intelligence

Espicom Business Intelligence is a UK-based company with a 30-year pedigree providing business intelligence on Medical Devices, Pharmaceuticals & Healthcare and Therapeutics across global markets.

Table of Contents

CONTENTS

Executive Summary

SWOT Analysis

  • Malaysia Pharmaceuticals And Healthcare Industry SWOT
  • Malaysia Political SWOT
  • Malaysia Economic SWOT
  • Malaysia Business Environment SWOT

Pharmaceutical Risk/Reward Ratings

  • Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q113
  • Rewards
  • Risks

Malaysia - Market Summary

Regulatory Regime

  • Table: Drug Applications by Type, 2002-10
  • Table: Registered Pharmaceutical Products by Type, 2002-10
  • Regulatory Developments
  • Bioequivalence
  • Regional Collaboration
  • Pharmaceutical And Medical Advertising
  • Labelling Requirements
  • Intellectual Property Regime
  • Counterfeit Pharmaceuticals
  • Compulsory Licensing
  • Free Trade Agreements
  • Pricing And Reimbursement

Industry Trends And Developments

  • Epidemiology
  • Non-Communicable Diseases
  • Communicable Diseases
  • Healthcare Sector
    • Table: 2011 Entry Points Projects Summary
  • Health Insurance
    • Table: Main Features Of 1Care
  • Healthcare Sector Funding
    • Table: Public Sector And Private Sector Healthcare Developments
  • Medical Tourism
  • Biotechnology And Research
  • Clinical Trials
  • Clinical Trials Industry Developments
  • Medical Devices
  • Leading Medical Device Players
  • Recent Medical Devices Industry Developments

Industry Forecast Scenario

  • Overall Market Forecast
    • Table: Pharmaceutical Sales Indicators 2008-2016
  • Key Growth Factors - Industry
    • Table: Healthcare Expenditure Indicators 2008-2016
    • Table: Healthcare Governmental Indicators 2008-2016
    • Table: Healthcare Private Indicators 2008-2016
  • Key Growth Factors - Macroeconomic
    • Table: Macro Indicators
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Sales Indicators 2008-2016
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators 2008-2016
  • Generic Drug Market Forecast
    • Table: Generic Drug Sales Indicators 2008-2016
  • OTC Medicine Market Forecast
    • Table: OTC Medicine Sales Indicators 2008-2016
  • Pharmaceutical Trade Forecast
    • Table: Exports and Imports Indicators 2008-2016
  • Medical Device Market Forecast
    • Table: Medical Devices Sales Indicators 2008-2016
  • Other Healthcare Data Forecasts
  • Key Risks To BMI's Forecast Scenario

Competitive Landscape

  • Domestic Pharmaceutical Industry
  • Foreign Pharmaceutical Industry
    • Table: Leading Malaysian Pharmaceutical And Healthcare Companies
  • Company Activities
  • Halal Medicine
  • Traditional Medicine
  • Pharmaceutical Distribution
    • Table: Drug Wholesalers & Importers, 2002-10

Company Profiles

  • Local Companies
  • Pharmaniaga
  • Prime Pharmaceutical
  • Bumimedic
  • Hovid
  • Chemical Company of Malaysia
  • Kotra Pharma
  • Multinational Companies
  • GlaxoSmithKline
  • Pfizer
  • Novartis
  • Merck & Co
  • Sanofi
  • Eli Lilly Malaysia
  • Ranbaxy Malaysia

Demographic Outlook

  • Table: Population By Age Group, 1990-2020 ('000)
  • Table: Population By Age Group, 1990-2020 (% of total)
  • Table: Key Population Ratios, 1990-2020
  • Table: Rural/Urban Population Split, 1990-2020

Glossary

BMI Methodology

  • How We Generate Our Pharmaceutical Industry Forecasts
  • Pharmaceuticals Risk/Reward Ratings Methodology
  • Ratings Overview
    • Table: Pharmaceutical Business Environment Indicators
  • Weighting
    • Table: Weighting Of Components
  • Sources
Back to Top